ADDED
The number of outstanding shares of the registrant s par value $0.001 common stock as of the close of business on March 2, 2026 was 122,045,049 .
1 to the Purchase and Sale Agreement ANDA Abbreviated New Drug Application ANVISA Brazilian Health Regulatory Agency API Active Pharmaceutical Ingredients AQST Common Stock symbol for Aquestive Therapeutics, Inc.
ARO Asset Retirement Obligations ARS Acute Repetitive Seizures ASC Accounting Standards Codification Assertio Assertio Holdings, Inc.
Food and Drug Administration FDAAA The Food and Drug Administration Amendments Act of 2007 FDCA The Federal Food, Drug, and Cosmetic Act FDIC Federal Deposit Insurance Corporation FDII Foreign Derived Intangible Income First Amendment First amendment to the Sunovion License Agreement GAAP Generally Accepted Accounting Principles GCP Good Clinical Practice GLP Good Laboratory Practice Haisco Haisco Pharmaceutical Group Co., Ltd.
Department of Health and Human Services HIPAA Health Insurance Portability and Accountability Act of 1996 HITECH Health Information Technology for Economic and Clinical Health Act HF Human Factors IND Investigational New Drug Application Indenture Agreement Agreement governing the 13.5% Senior Secured Notes Indivior Indivior UK Limited (formerly, Reckitt Benckiser Pharmaceuticals Inc and Indivior Inc.) Indivior Amendment 11 Amendment No.
(with subsequent amendments collectively) IM Intramuscular IRB Institutional Review Board Lincoln Park Lincoln Park Capital Fund, LLC Marathon Marathon Asset Management MHRA Medicines and Healthcare Products Regulatory Agency Monetization Agreement Purchase and Sale Agreement between Aquestive and Sunovion MSSP Managed Security Services Provider MTPA Mitsubishi Tanabe Pharma Holdings America, Inc.
N/M Not Meaningful, used in percentage changes Nasdaq The Nasdaq Stock Market NDA New Drug Application NDS New Drug Submission New Warrants Warrants to purchase 2,750,000 shares of Common Stock NIH National Institutes of Health NIST CSF National Institute of Standards and Technology Cybersecurity Framework ODE Orphan Drug Exclusivity PD Pharmacodynamics PDMA The U.S.
and abroad, including Anaphylm, if such product candidates should be approved by the FDA and other regulatory authorities, and our licensed products in the U.S.
and abroad of Anaphylm, AQST-108, Libervant and our other product candidates, should these product candidates be approved by the FDA and other regulatory authorities, and for our licensed products in the U.S.
We are advancing our late stage non-device based epinephrine prodrug product candidate for the treatment of severe allergic reactions, including anaphylaxis, under the "Anaphylm " trade name, and our AdrenaVerse epinephrine prodrug pipeline platform.
REMOVED
The number of outstanding shares of the registrant s par value $0.001 common stock as of the close of business on March 3, 2025 was 98,871,369 .
Exhibits, Financial Statement Schedules 81 GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS The following terms, abbreviations and acronyms are used to identify frequently used terms and phrases that may be used in this report: TERM DEFINITION 12.5% Notes 12.5% Senior Secured Notes due 2025 13.5% Notes 13.5% Senior Secured Notes ADHD Attention Deficit Hyperactivity Disorder ALS Amyotrophic Lateral Sclerosis ANDA Abbreviated New Drug Application ANVISA Brazilian Health Regulatory Agency API Active Pharmaceutical Ingredients AQST Common Stock symbol for Aquestive Therapeutics, Inc.
ARO Asset Retirement Obligations ASC Accounting Standards Codification Assertio Assertio Holdings, Inc.
Assertio Agreement License Agreement between Aquestive and Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, ASU Accounting Standards Updates ATM At-The-Market facility for the purchase of AQST Common Stock Base Indenture Indenture for the 12.5% Notes BBA Bipartisan Budget Act of 2018 BDSI BioDelivery Sciences International, Inc.
Food and Drug Administration FDAAA The Food and Drug Administration Amendments Act of 2007 FDCA The Federal Food, Drug, and Cosmetic Act FDIC Federal Deposit Insurance Corporation FDII Foreign Derived Intangible Income First Amendment First amendment to the Sunovion License Agreement Fortovia Fortovia Therapeutics Inc.
(previously Midatech Pharma PLC FQHC Federally Qualified Health Center GAAP Generally Accepted Accounting Principles GLP Good Laboratory Practice Haisco Haisco Pharmaceutical Group Co., Ltd.
Department of Health and Human Services HIPAA Health Insurance Portability and Accountability Act of 1996 HITECH Health Information Technology for Economic and Clinical Health Act IND Investigational New Drug Application Indenture Agreement Agreement governing the 13.5% Senior Secured Notes Indivior Indivior Inc.
(formerly, Reckitt Benckiser Pharmaceuticals Inc) Indivior Amendment 11 Amendment No.
(with subsequent amendments collectively) IRB Institutional Review Board Lincoln Park Lincoln Park Capital Fund, LLC Lincoln Park Purchase Agreement Purchase Agreement with Lincoln Park Capital Fund, LLC Marathon Marathon Asset Management Monetization Agreement Purchase and Sale Agreement between Aquestive and Sunovion MSSP Managed Security Services Provider MTHA Mitsubishi Tanabe Pharma Holdings America, Inc.
N/M Not Meaningful, used in percentage changes Nasdaq The Nasdaq Stock Market NDA New Drug Application New Warrants Warrants to purchase 2,750,000 shares of Common Stock NIH National Institutes of Health ODE Orphan Drug Exclusivity PD Pharmacodynamics PDMA The U.S.